Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spero Therapeutics reports progress in drug candidates and financial stability

Spero Therapeutics showcased progress in key drug candidates and financial stability.
Efficient management of expenses and strong cash position support future operations.
Challenges include successful Phase III trials and proof of concept for key treatments.
Opportunities lie in market potential for drug candidates and positive financial outlook.

Spero Therapeutics advances clinical programs and strengthens financial position

Spero Therapeutics demonstrated strong clinical and financial performance in Q1 2023, with a robust pipeline and efficient cost management.
While facing timeline challenges and the need for regulatory milestones, the company's strengths in infectious disease treatments and strategic partnerships present growth opportunities.
By addressing challenges, leveraging strengths, and capitalizing on opportunities, Spero is poised for continued success and potential market leadership in the pharmaceutical sector.

Spero Therapeutics reports Q2 progress with strategic leadership changes

Spero Therapeutics reported Q2 revenues of $2.7 million with a net loss of $11.9 million, holding $77.7 million in cash.
Progress in late-stage clinical programs and management changes signal strategic advancements and leadership continuity.
Challenges include managing R&D investments, competitive market dynamics, and clear execution of growth strategies.
Opportunities lie in revenue growth from milestones, pipeline expansion, differentiation strategies, and strategic partnerships.

Spero Therapeutics reports strong Q3 performance amidst strategic shifts

Spero Therapeutics showcased solid revenue generation and cash reserves in Q3 2023, underpinned by strategic partnerships and pipeline advancements.
While facing challenges such as increased expenses and impairment costs, the company's leadership changes and innovative programs position it for long-term success.
Opportunities lie in upcoming clinical data releases, expansion of product pipelines, and substantial revenue potential from key partnerships, signaling a promising outlook for Spero.

Spero Therapeutics excels in antibiotic development with strong financial backing

Spero Therapeutics demonstrated strong performance in advancing key programs and securing financial support, positioning the company for future growth.
While facing challenges in enrollment and funding, the opportunities in addressing critical infections present a promising outlook for Spero Therapeutics.

Spero Therapeutics reports Q2 revenue growth amidst leadership transition

Spero Therapeutics showcased solid revenue but faced rising R&D costs and leadership changes.
The company's financial stability is supported by cash reserves and expected milestone payments.
Opportunities lie in pipeline advancements, upcoming data releases, and strategic investor communication.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

Source: Shutterstock Spero Therapeutics (NASDAQ: SPRO ) stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of complicated urinary tract infection (cUTI).

Why Is Spero Therapeutics (SPRO) Stock Up 15% Today?

American Virtual Cloud Technologies

HyreCar

Here's what you need to know about buying penny stocks on September 7th The post Are These Penny Stocks on Your September Buy List? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Penny Stocks on Your September Buy List?

Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Spero Therapeutics, Inc. (SPRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer David Melnick - Consultant & Senior Clinical Advisor Sath Shukla - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Louise Chen - Cantor Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutics Second Quarter 2022 Financial Results Conference Call.

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates

Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

NEW YORK , July 25, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-04154, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spero securities between May 6, 2021 and May 2, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO

New York, New York--(Newsfile Corp. - July 25, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spero Therapeutics, Inc. (NASDAQ: SPRO) between May 6, 2021 and May 2, 2022, both dates inclusive (the "Class Period"), of the important than July 25, 2022 lead plaintiff deadline.

SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class Action - SPRO

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Spero securities between October 28, 2021 and May 2, 2022, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.

Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and Last Few Hours to Actively Participate

Los Angeles, California--(Newsfile Corp. - July 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spero Therapeutics, Inc. ("Spero" or "the Company") (NASDAQ: SPRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , July 25, 2022 /PRNewswire/ -- Attention Spero Therapeutics, Inc. ("Spero") (NASDAQ: SPRO) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 6, 2021 and May 2, 2022. If you suffered a loss on your investment in Spero, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spero Investors of a Lead Plaintiff Deadline of July 25, 2022

New York, New York--(Newsfile Corp. - July 22, 2022) - Levi & Korsinsky, LLP notifies investors in Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) of a class action securities lawsuit.The lawsuit on behalf of Spero investors has been commenced in the the United States District Court for the Eastern District of New York. Affected investors purchased or otherwise acquired certain Spero Therapeutics, Inc. securities between May 6, 2021 and May 2, 2022. Follow...

Spero Class Action: Levi & Korsinsky Reminds Spero Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 25, 2022 - SPRO

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) securities between May 6, 2021 and May 2, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On October 28, 2021, Spero announced that it had submitted a New

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Los Angeles, California--(Newsfile Corp. - July 22, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spero Therapeutics, Inc. ("Spero" or "the Company") (NASDAQ: SPRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 28, 2021 and May 2, 2022, inclusive...

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , July 22, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spero Therapeutics, Inc. (NASDAQ: SPRO). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/spero-therapeutics-inc-loss-submission-form/?id=30073&from=4 The lawsuit seeks to recover losses for shareholders who purchased Spero between May 6, 2021 and May 2, 2022.

SPRO SHAREHOLDER ALERT: Jakubowitz Law Reminds Spero Shareholders of a Lead Plaintiff Deadline of July 25, 2022

NEW YORK , July 21, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) and certain of its officers.  The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-04154, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spero securities between May 6, 2021 and May 2, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers - SPRO

LOS ANGELES , July 21, 2022 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO). Class Period: May 6, 2021 – May 2, 2022 Lead Plaintiff Deadline: July 25, 2022 If you wish to serve as lead plaintiff of the Spero lawsuit, you can submit your contact information at www.glancylaw.com/cases/spero-therapeutics-inc/.

SPRO Investors Have Opportunity to Lead Spero Therapeutics, Inc. Securities Fraud Lawsuit

Los Angeles, California--(Newsfile Corp. - July 21, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spero Therapeutics, Inc. ("Spero" or "the Company") (NASDAQ: SPRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 28, 2021 and May 2, 2022, inclusive...

MONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , July 21, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Spero investors who were adversely affected by alleged securities fraud between May 6, 2021 and May 2, 2022.

SPRO LAWSUIT ALERT: Levi & Korsinsky Notifies Spero Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , July 20, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spero Therapeutics, Inc.. Shareholders who purchased shares of SPRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 25, 2022 - (NASDAQ: SPRO)

NEW YORK , July 19, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spero Therapeutics, Inc. (NASDAQ: SPRO) alleging that the Company violated federal securities laws. Class Period: October 28, 2021 to May 2, 2022 Lead Plaintiff Deadline: July 25, 2022 No obligation or cost to you.

SPRO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 25, 2022 in the Class Action Filed on Behalf of Spero Therapeutics, Inc. Shareholders

New York, New York--(Newsfile Corp. - July 18, 2022) - Levi & Korsinsky, LLP notifies investors in Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) of a class action securities lawsuit.The lawsuit on behalf of Spero investors has been commenced in the the United States District Court for the Eastern District of New York. Affected investors purchased or otherwise acquired certain Spero Therapeutics, Inc. securities between May 6, 2021 and May 2, 2022. Follow...

News for Spero Therapeutics Stock (SPRO)